Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.48 |
| ▸ | HRH4 | Q9H3N8 | 6/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | SPR | P35270 | 1/20 | 0.45 |
| ▸ | CCNC | P24863 | 1/20 | 0.44 |
| ▸ | CDK8 | P49336 | 1/20 | 0.44 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.44 |
| ▸ | SYK | P43405 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30552687 | 0.85 | POLB (0.59) | POLBSMN1; SMN2HRH3HRH4MEN1 | |
| SCHEMBL25431128 | 0.85 | POLB (0.59) | POLBSMN1; SMN2HRH3HRH4MEN1 | |
| SCHEMBL31428559 | 0.82 | POLB (0.56) | POLBSMN1; SMN2HRH3HRH4NPC1 | |
| SCHEMBL30163500 | 0.82 | POLB (0.56) | POLBSMN1; SMN2HRH3HRH4NPC1 | |
| SCHEMBL25376559 | 0.81 | POLB (0.55) | POLBSMN1; SMN2HRH3HRH4MEN1 | |
| SCHEMBL14845692 | 0.79 | NPC1 (0.76) | POLBSMN1; SMN2HRH3HRH4NPC1 | |
| SCHEMBL13175659 | 0.77 | AKR1C3 (0.70) | POLBNPC1RAB9AMEN1KMT2A | |
| SCHEMBL18889251 | 0.77 | HRH4 (0.60) | POLBSMN1; SMN2HRH3HRH4NPC1 | |
| SCHEMBL8264513 | 0.77 | FGFR1 (0.55) | SMN1; SMN2KMT2A | |
| SCHEMBL2770082 | 0.75 | HRH4 (0.71) | POLBSMN1; SMN2HRH3HRH4NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250091994-A1 | RAS/RAF BINDING INHIBITOR COMPOUND | NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY (JP) | 2025-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250091994-A1 | RAS/RAF BINDING INHIBITOR COMPOUND | BRAF, RAF1, NRAS | POLB 3285/4885SMN1; SMN2 4832/4885HRH3 2324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.